Treatment elements of GMALL studies 04/89 and 05/93
| Drug . | Dose . | Days of administration . |
|---|---|---|
| Induction I | ||
| Prednisone (po) | 60 mg/m2 | 1-28, then taper over 3 × 3 days |
| Vincristine (iv) | 2 mg | 1, 8, 15, 22 |
| Daunorubicin (iv, 30 min) | 45 mg/m2 | 1, 8, 15, 22 |
| Methotrexate (it) | 15 mg | 1 |
| L-Asparaginase (iv, 30 min) | 5 000 IU/m2 | 15-28, every other day |
| Induction II | ||
| Cyclophosphamide (iv) | 1 000 (650) mg/m2 | 29, 43, 57 |
| Cytarabine (iv, 1 h) | 75 mg/m2 | 31-34, 38-41, 45-48, 52-55 |
| 6-Mercaptopurine (orally) | 60 mg/m2 | 29-57 |
| Methotrexate (it) | 15 mg | 31, 38, 45, 52 |
| Consolidation I | ||
| HDAC/MITOX | ||
| Cytarabine (iv, 3 h) | 2* × 1 000 mg/m2 | 1-4 |
| Mitoxantrone (iv, 30 min) | 10 mg/m2 | 3-5 (2-5) |
| HDMTX/ASP | ||
| Methotrexate (iv, 24 h) | 1 500 mg/m2 | 1, 15 |
| Asparaginase | 10 000 U/m2 | 2, 16 |
| 6-Mercaptopurine | 25 mg/m2 | 1-5, 15-19 |
| Reinduction I | ||
| Prednisolone (orally) | 60 mg/m2 | 1-28 |
| Vincristine (iv) | 2 mg | 1, 8, 15, 22 |
| Adriamycine (iv, 30 min) | 25 mg/m2 | 1, 8, 15, 22 |
| Triple prophylaxis (it) | 1 | |
| Reinduction II | ||
| Cyclophosphamide (iv) | 1 000 (650) mg/m2 | 29 |
| Cytarabine (iv, 1 h) | 75 mg/m2 | 31-34, 38-41 |
| 6-Thioguanine (orally) | 60 mg/m2 | 29-42 |
| Triple prophylaxis (it) | 29 | |
| Consolidation II | ||
| VM26/ARAC† | ||
| Etoposide (iv, 1 h) | 100 (60) mg/m2 | 1-5 |
| Cytarabine (iv, 1 h) | 150 (75) mg/m2 | 1-5 |
| CYCLO/ARAC | ||
| Cyclophosphamide (iv) | 1 000 mg/m2 | d 1 |
| Cytarabine (iv, 24 h) | 500 mg/m2 | d 1 |
| Triple prophylaxis | ||
| Methotrexate (it) | 15 mg | |
| Cytarabine (it) | 40 mg | |
| Dexamethasone (it) | 4 mg |
| Drug . | Dose . | Days of administration . |
|---|---|---|
| Induction I | ||
| Prednisone (po) | 60 mg/m2 | 1-28, then taper over 3 × 3 days |
| Vincristine (iv) | 2 mg | 1, 8, 15, 22 |
| Daunorubicin (iv, 30 min) | 45 mg/m2 | 1, 8, 15, 22 |
| Methotrexate (it) | 15 mg | 1 |
| L-Asparaginase (iv, 30 min) | 5 000 IU/m2 | 15-28, every other day |
| Induction II | ||
| Cyclophosphamide (iv) | 1 000 (650) mg/m2 | 29, 43, 57 |
| Cytarabine (iv, 1 h) | 75 mg/m2 | 31-34, 38-41, 45-48, 52-55 |
| 6-Mercaptopurine (orally) | 60 mg/m2 | 29-57 |
| Methotrexate (it) | 15 mg | 31, 38, 45, 52 |
| Consolidation I | ||
| HDAC/MITOX | ||
| Cytarabine (iv, 3 h) | 2* × 1 000 mg/m2 | 1-4 |
| Mitoxantrone (iv, 30 min) | 10 mg/m2 | 3-5 (2-5) |
| HDMTX/ASP | ||
| Methotrexate (iv, 24 h) | 1 500 mg/m2 | 1, 15 |
| Asparaginase | 10 000 U/m2 | 2, 16 |
| 6-Mercaptopurine | 25 mg/m2 | 1-5, 15-19 |
| Reinduction I | ||
| Prednisolone (orally) | 60 mg/m2 | 1-28 |
| Vincristine (iv) | 2 mg | 1, 8, 15, 22 |
| Adriamycine (iv, 30 min) | 25 mg/m2 | 1, 8, 15, 22 |
| Triple prophylaxis (it) | 1 | |
| Reinduction II | ||
| Cyclophosphamide (iv) | 1 000 (650) mg/m2 | 29 |
| Cytarabine (iv, 1 h) | 75 mg/m2 | 31-34, 38-41 |
| 6-Thioguanine (orally) | 60 mg/m2 | 29-42 |
| Triple prophylaxis (it) | 29 | |
| Consolidation II | ||
| VM26/ARAC† | ||
| Etoposide (iv, 1 h) | 100 (60) mg/m2 | 1-5 |
| Cytarabine (iv, 1 h) | 150 (75) mg/m2 | 1-5 |
| CYCLO/ARAC | ||
| Cyclophosphamide (iv) | 1 000 mg/m2 | d 1 |
| Cytarabine (iv, 24 h) | 500 mg/m2 | d 1 |
| Triple prophylaxis | ||
| Methotrexate (it) | 15 mg | |
| Cytarabine (it) | 40 mg | |
| Dexamethasone (it) | 4 mg |